ES2488628T3 - Terapia de combinación y método de evaluación de la resistencia a un tratamiento - Google Patents

Terapia de combinación y método de evaluación de la resistencia a un tratamiento Download PDF

Info

Publication number
ES2488628T3
ES2488628T3 ES11719829.1T ES11719829T ES2488628T3 ES 2488628 T3 ES2488628 T3 ES 2488628T3 ES 11719829 T ES11719829 T ES 11719829T ES 2488628 T3 ES2488628 T3 ES 2488628T3
Authority
ES
Spain
Prior art keywords
evaluation method
combination therapy
resistance evaluation
treatment resistance
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11719829.1T
Other languages
English (en)
Inventor
John Frederick Boylan
Wei He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2488628T3 publication Critical patent/ES2488628T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para la determinación de la resistencia de un sujeto a un tratamiento contra un trastorno proliferativo con el compuesto 2,2-dimetil-N-((S)-6-oxo-6,7-dihidro-5H-dibenzo[b,d]azepin-7-il)-N'-(2,2,3,3,3-pentafluoro-propil)- malonamida (Compuesto I), que comprende medir el nivel de un biomarcador presente en una muestra biológica obtenida de dicho sujeto, siendo dicho biomarcador IL-6 o IL-8.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
    imagen2
ES11719829.1T 2010-05-19 2011-05-17 Terapia de combinación y método de evaluación de la resistencia a un tratamiento Active ES2488628T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34624710P 2010-05-19 2010-05-19
US346247P 2010-05-19
PCT/EP2011/057909 WO2011144583A1 (en) 2010-05-19 2011-05-17 Combination therapy and method for assessing resistance to treatment

Publications (1)

Publication Number Publication Date
ES2488628T3 true ES2488628T3 (es) 2014-08-28

Family

ID=44063206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11719829.1T Active ES2488628T3 (es) 2010-05-19 2011-05-17 Terapia de combinación y método de evaluación de la resistencia a un tratamiento

Country Status (12)

Country Link
US (1) US8309299B2 (es)
EP (1) EP2572198B1 (es)
JP (1) JP5680744B2 (es)
KR (2) KR101539138B1 (es)
CN (1) CN102893155B (es)
BR (1) BR112012027970A2 (es)
CA (1) CA2798181A1 (es)
ES (1) ES2488628T3 (es)
HK (1) HK1176403A1 (es)
MX (1) MX2012013305A (es)
RU (1) RU2587053C2 (es)
WO (1) WO2011144583A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023151A2 (pt) * 2013-03-15 2017-07-18 Nanobiosym Inc sistemas e métodos para análise de dispositivo móvel de ácidos nucléicos e proteínas
US10933417B2 (en) 2013-03-15 2021-03-02 Nanobiosym, Inc. Systems and methods for mobile device analysis of nucleic acids and proteins
JP6250351B2 (ja) * 2013-09-30 2017-12-20 シスメックス株式会社 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
CN106093217B (zh) * 2015-05-29 2019-02-22 中国人民解放军第三0二医院 一种评价中西药注射剂序贯联用间隔时间的方法
WO2020163222A1 (en) * 2019-02-04 2020-08-13 Promab Biotechnologies, Inc. Nucleic acid sequence encoding chimeric antigen receptor and a short hairpin rna sequence for il-6 or a checkpoint inhibitor
WO2021243291A2 (en) * 2020-05-28 2021-12-02 University Of Massachusetts Oligonucleotides for sars-cov-2 modulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04325095A (ja) * 1991-04-26 1992-11-13 Tosoh Corp 抗ヒトｉｌ−６モノクロ−ナル抗体及び該抗体を使用するｉｌ−６の測定方法
JPH05215749A (ja) * 1992-02-07 1993-08-24 Toray Ind Inc ヒトインタ−ロイキン−８の免疫学的測定法
ATE258599T1 (de) * 1997-02-21 2004-02-15 Genentech Inc Antikörperfragment-polymerkonjugate
JP2003511696A (ja) 1999-10-13 2003-03-25 インサイト・ゲノミックス・インコーポレイテッド 多重的サイトカイン分析
US7349913B2 (en) 2003-08-21 2008-03-25 Microsoft Corporation Storage platform for organizing, searching, and sharing data
PT1711470E (pt) 2003-09-09 2009-05-21 Hoffmann La Roche Derivados de malonamida que bloqueiam a actividade de gama-secretase
CN1977051B (zh) * 2004-02-20 2013-07-17 加利福尼亚大学董事会 唾液mRNA分布型分析、生物标记及其相关方法和试剂盒
JP4839674B2 (ja) * 2004-05-14 2011-12-21 東レ株式会社 標的物質を迅速簡便に検出する方法およびそのための酵素免疫学的キット
RU2440342C2 (ru) * 2006-03-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ
KR101096476B1 (ko) * 2006-09-20 2011-12-20 에프. 호프만-라 로슈 아게 4-옥소-2,3,4,5-테트라히드로-벤조[ｂ][1,4]디아제핀 유도체
EP2109604A1 (en) * 2007-02-02 2009-10-21 F. Hoffmann-Roche AG 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
EP2147115A4 (en) * 2007-04-16 2010-05-05 CARDIOBIOINDEX / CARDIOBIOSCORE AND THE USE OF THE SPOKING PROTEOME IN CARDIOVASCULAR DIAGNOSTICS
EP2244713A1 (en) * 2008-01-11 2010-11-03 F. Hoffmann-La Roche AG Use of a gamma-secretase inhibitor for treating cancer
CN101608222A (zh) * 2008-06-20 2009-12-23 上海主健生物工程有限公司 糖尿病遗传检测试剂盒

Also Published As

Publication number Publication date
KR101718260B1 (ko) 2017-03-20
EP2572198B1 (en) 2014-06-25
RU2012151434A (ru) 2014-06-27
CN102893155A (zh) 2013-01-23
HK1176403A1 (zh) 2013-07-26
CA2798181A1 (en) 2011-11-24
WO2011144583A1 (en) 2011-11-24
JP5680744B2 (ja) 2015-03-04
JP2013527454A (ja) 2013-06-27
US20110287025A1 (en) 2011-11-24
KR101539138B1 (ko) 2015-07-23
MX2012013305A (es) 2013-02-01
RU2587053C2 (ru) 2016-06-10
US8309299B2 (en) 2012-11-13
KR20130009884A (ko) 2013-01-23
EP2572198A1 (en) 2013-03-27
KR20150065931A (ko) 2015-06-15
CN102893155B (zh) 2016-01-20
BR112012027970A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
ES2488628T3 (es) Terapia de combinación y método de evaluación de la resistencia a un tratamiento
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
CL2009000040A1 (es) Uso del compuesto 2,2-dimetil-n-((s)-6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-il)-n'-(2,2,3,3,3-pentafluor-propil)-malonamida para el tratamiento del cancer, en particular de tumores solidos, metodos de fabricacion y kit que lo contiene.
BR112012002954A2 (pt) metodo para diagnosticar um disturbio de tireoide, metodo para determinar a capacidade de um composto de induzir um disturbio da tireoide metodo para identificar uma substancia para tratar um disturbio da tireoide, dispositivo para diagnosticar um disturbio da tireoide e uso de pelo menos um analito
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112014013082A2 (pt) método para detectar adutos nucleossomos
WO2011109372A8 (en) Ultra-sensitive detection of molecules using dual detection methods
BR112013008707A2 (pt) montagem de calibração da concentração do agente de constrate da imagem de ressonância magnética, sistema de imagem da ressonância magnética para imagem de t1 melhorada pelo agente de constrate, produto de programa de computador e método implementado por computador para determinar uma calibração t1
MX2017011312A (es) Metodos para la cuantificacion de los niveles de insulina por espectrometria de masas.
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
BR112014031143B8 (pt) Método para quantificar células imunes em tecidos tumorais e suas aplicações
MX366275B (es) Metodos para detectar y medir la agregacion.
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
IN2014MN02266A (es)
BR112015003046A2 (pt) sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador.
EP4220170A3 (en) Method for detecting a solid tumor cancer
BR112014032326A2 (pt) caracterização de amostra de fluido heterogêneo
MX2019011775A (es) Metodos para la cuantificacion de insulina y peptido c.
EA201071324A1 (ru) Система и способы измерения профилей биомаркеров
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
BRPI0912136A2 (pt) métodos para diagnosticar proliferação peroxissomal aumentada e para identificar uma substância para tratar proliferação peroxissomal aumentada, e, uso de pelo menos cinco analitos e de meios para a determinação de pelo menos cinco analitos
BR112014012366A2 (pt) processos para a detecção de triiodotironina inversa por espectrometria de massa
FR2977674B1 (fr) Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule